Stroke (Hoboken, N.J.) · 2024
MARVEL: A Randomized Double-Blind, Placebo-Controlled Trial in Patients Undergoing Endovascular Therapy: Study Rationale and Design.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yang Qingwu, Guo Changwei, Yue Chengsong, Yang Jie, Li Linyu, Peng Zhouzhou, Hu Jinrong, Huang Jiandi, Song Jiaxing, Huang Jiacheng, Kong Weilin, Yu Nizhen, Yang Dahong, Liu Xiang, Wang Duolao, Nogueira Raul G, Li Fengli, Nguyen Thanh N, Zi Wenjie
Аннотация
BACKGROUND: Steroids have pleiotropic neuroprotective actions including the regulation of inflammation and apoptosis which may influence the effects of ischemia on neurons, glial cells, and blood vessels. The effect of low-dose methylprednisolone in patients with acute ischemic stroke in the endovascular therapy era remains unknown. This trial investigates the efficacy and safety of low-dose methylprednisolone (2 mg/kg IV for 3 days) as adjunctive therapy for patients with acute ischemic stroke undergoing endovascular therapy within 24 hours from symptom onset.
METHODS: The MARVEL (Methylprednisolone as Adjunctive Therapy for Acute Large Vessel Occlusion: A Randomized Double-Blind, Placebo-Controlled Trial in Patients Undergoing Endovascular Therapy) trial is an investigator-initiated, prospective, randomized, double-blind, placebo-controlled multicenter clinical trial. Up to 1672 eligible patients with anterior circulation large-vessel occlusion stroke presenting within 24 hours from symptom onset are planned to be consecutively randomized to receive methylprednisolone or placebo in a 1:1 ratio across 82 stroke centers in China.
RESULTS: The primary outcome is the ordinal shift in the modified Rankin scale score at 90 days. Secondary outcomes include 90-day functional independence (modified Rankin scale score, 0-2). The primary safety end points include mortality rate at 90 days and symptomatic intracerebral hemorrhage within 48 hours of endovascular therapy.
CONCLUSION: The MARVEL trial will provide evidence of the efficacy and safety of low-dose methylprednisolone as adjunctive therapy for patients with anterior circulation large-vessel occlusion stroke undergoing endovascular therapy.
METHODS: The MARVEL (Methylprednisolone as Adjunctive Therapy for Acute Large Vessel Occlusion: A Randomized Double-Blind, Placebo-Controlled Trial in Patients Undergoing Endovascular Therapy) trial is an investigator-initiated, prospective, randomized, double-blind, placebo-controlled multicenter clinical trial. Up to 1672 eligible patients with anterior circulation large-vessel occlusion stroke presenting within 24 hours from symptom onset are planned to be consecutively randomized to receive methylprednisolone or placebo in a 1:1 ratio across 82 stroke centers in China.
RESULTS: The primary outcome is the ordinal shift in the modified Rankin scale score at 90 days. Secondary outcomes include 90-day functional independence (modified Rankin scale score, 0-2). The primary safety end points include mortality rate at 90 days and symptomatic intracerebral hemorrhage within 48 hours of endovascular therapy.
CONCLUSION: The MARVEL trial will provide evidence of the efficacy and safety of low-dose methylprednisolone as adjunctive therapy for patients with anterior circulation large-vessel occlusion stroke undergoing endovascular therapy.